WO2002100433A1 - Medicinal compositions - Google Patents

Medicinal compositions Download PDF

Info

Publication number: WO2002100433A1
Authority: WO; WIPO (PCT)
Prior art keywords: salt; compound; group; pyridyl group; inhibiotry
Prior art date: 2001-06-11

Application number

PCT/JP2002/005726

Other languages

English (en)

French (fr)

Inventor

Shigenori Ohkawa

Ken-Ichi Naruo

Shigeru Morimoto

Yoshinori Nagase

Seiji Miwatashi

Original Assignee

Takeda Chemical Industries, Ltd.

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2001-06-11

Filing date

2002-06-10

Publication date

2002-12-19

2002-06-10 Application filed by Takeda Chemical Industries, Ltd. filed Critical Takeda Chemical Industries, Ltd.

2002-06-10 Priority to CA002450400A priority Critical patent/CA2450400A1/en

2002-06-10 Priority to EP20020733431 priority patent/EP1402900A1/en

2002-06-10 Priority to US10/480,551 priority patent/US20050080113A1/en

2002-12-19 Publication of WO2002100433A1 publication Critical patent/WO2002100433A1/ja

Links

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

PCT/JP2002/005726 2001-06-11 2002-06-10 Medicinal compositions WO2002100433A1 (en)

Priority Applications (3)

Application Number	Priority Date	Filing Date	Title
CA002450400A CA2450400A1 (en)	2001-06-11	2002-06-10	Medicinal compositions
EP20020733431 EP1402900A1 (en)	2001-06-11	2002-06-10	Medicinal compositions
US10/480,551 US20050080113A1 (en)	2001-06-11	2002-06-10	Medicinal compositions

Applications Claiming Priority (4)

Application Number	Priority Date	Filing Date	Title
JP2001175224		2001-06-11
JP2001-175273		2001-06-11
JP2001-175224		2001-06-11
JP2001175273		2001-06-11

Publications (1)

Publication Number	Publication Date
WO2002100433A1 true WO2002100433A1 (en)	2002-12-19

Family

ID=26616680

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
PCT/JP2002/005726 WO2002100433A1 (en)	2001-06-11	2002-06-10	Medicinal compositions

Country Status (4)

Country	Link
US (1)	US20050080113A1 (ja)
EP (1)	EP1402900A1 (ja)
CA (1)	CA2450400A1 (ja)
WO (1)	WO2002100433A1 (ja)

Cited By (12)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO2004021988A2 (en) *	2002-09-05	2004-03-18	Scios Inc.	Treatment of pain by inhibition of p38 map kinase
WO2004026307A1 (en) *	2002-09-18	2004-04-01	Pfizer Products Inc.	Triazole derivatives as transforming growth factor (tgf) inhibitors
WO2006137658A1 (en) *	2005-06-20	2006-12-28	Dongbu Hitek Co., Ltd.	New substituted 1,3-thiazole derivatives or pharmaceutically acceptable salts thereof having immunosuppression and inflammation inhibitory acitivity, intermediate compounds or pharmaceutically acceptable salts thereof, a process for the preparation thereof, and pharmaceutical composition comprising the same
WO2006137527A1 (ja)	2005-06-23	2006-12-28	Kyowa Hakko Kogyo Co., Ltd.	チアゾール誘導体
US7273936B2 (en)	2002-09-18	2007-09-25	Pfizer Inc.	Oxazole and thiazole compounds as transforming growth factor (TGF) inhibitors
US7410988B2 (en)	2004-08-13	2008-08-12	Genentech, Inc.	2-Amido-thiazole-based compounds exhibiting ATP-utilizing enzyme inhibitory activity, and compositions, and uses thereof
US8049016B2 (en)	2008-02-20	2011-11-01	Novartis Ag	Thiazole derivatives which inhibit stearoyl-CoA desaturase enzymes
US8063084B2 (en)	2006-08-15	2011-11-22	Novartis Ag	Heterocyclic compounds suitable for the treatment of diseases related to elevated lipid levels
US20130267509A1 (en) *	2003-12-26	2013-10-10	Kyowa Hakko Kirin Co., Ltd.	Thiazole derivatives
US9663529B2 (en)	2013-07-02	2017-05-30	Bristol-Myers Squibb Company	Tricyclic pyrido-carboxamide derivatives as rock inhibitors
US9914740B2 (en)	2013-07-02	2018-03-13	Bristol-Myers Squibb Company	Tricyclic pyrido-carboxamide derivatives as rock inhibitors
CN111757881A (zh) *	2018-01-15	2020-10-09	澳升控股有限公司	作为治疗剂的5-(嘧啶-4-基)噻唑-2-基脲衍生物

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
SI1180518T1 (sl) *	1999-04-23	2007-06-30	Takeda Pharmaceutical	5-piridil-1,3-azolne spojine, postopek za njihovo pripravo in njihova uporaba
US7344716B2 (en) *	2003-05-13	2008-03-18	Depuy Spine, Inc.	Transdiscal administration of specific inhibitors of pro-inflammatory cytokines
US7429378B2 (en) *	2003-05-13	2008-09-30	Depuy Spine, Inc.	Transdiscal administration of high affinity anti-MMP inhibitors
US8273347B2 (en) *	2003-05-13	2012-09-25	Depuy Spine, Inc.	Autologous treatment of degenerated disc with cells
US8895540B2 (en) *	2003-11-26	2014-11-25	DePuy Synthes Products, LLC	Local intraosseous administration of bone forming agents and anti-resorptive agents, and devices therefor
US7137864B2 (en) *	2004-07-12	2006-11-21	Swanson Melvin J	Methods and reagents for treating honeybees for parasitic mites
EP1810972B1 (en) *	2004-11-10	2012-01-25	Ono Pharmaceutical Co., Ltd.	Nitrogenous heterocyclic compound and pharmaceutical use thereof
MX2007006777A (es)	2004-12-06	2007-08-06	Avigen Inc	Ibudilast para tratar dolor neuropatico y sindromes asociados.
MY149143A (en) *	2006-01-18	2013-07-15	Amgen Inc	Thiazole compounds as protien kinase b (pkb) inhibitors
CH698658B1 (de) *	2006-04-24	2009-09-30	Mepha Ag	Orale pharmazeutische Formulierung mit schneller Freisetzung für Pyridylmethylsulfinyl-Benzimidazole.
ES2392116T3 (es) *	2007-01-30	2012-12-04	Avigen, Inc.	Procedimientos para el tratamiento del dolor agudo y subcrónico
US20080287402A1 (en) *	2007-05-03	2008-11-20	Johnson Kirk W	Use of a glial attenuator to prevent amplified pain responses caused by glial priming
AU2008276521B2 (en)	2007-07-17	2011-11-03	Amgen Inc.	Heterocyclic modulators of PKB
AU2008276512A1 (en) *	2007-07-17	2009-01-22	Amgen Inc.	Thiadiazole modulators of PKB
US8986696B2 (en) *	2007-12-21	2015-03-24	Depuy Mitek, Inc.	Trans-capsular administration of p38 map kinase inhibitors into orthopedic joints
US20090162351A1 (en) *	2007-12-21	2009-06-25	Depuy Spine, Inc.	Transdiscal administration of inhibitors of p38 MAP kinase
WO2009118589A2 (en) *	2008-03-24	2009-10-01	Wockhardt Research Centre	Orally disintegrating compositions of rhein or diacerein
WO2010018866A1 (ja) *	2008-08-14	2010-02-18	杏林製薬株式会社	安定化された医薬組成物
EP2198710A1 (de)	2008-12-19	2010-06-23	Bayer CropScience AG	Verwendung von 5-Pyridin-4yl-(1,3)Thiazole zur Bekämpfung phytopathogener Pilze
CA2794018C (en) *	2010-03-24	2016-05-10	Medical University Of South Carolina	Compositions and methods for the treatment of degenerative diseases
WO2012085650A1 (en) *	2010-12-22	2012-06-28	Purdue Pharma L.P.	Substituted pyridines as sodium channel blockers
AU2012205791B2 (en)	2011-01-10	2016-11-03	Invion, Ltd.	Use of beta-adrenergic inverse agonists for smoking cessation
DK2763993T3 (en)	2011-10-06	2017-07-24	Bayer Ip Gmbh	HETEROCYCLYLPYRI (MI) DINYLPYRAZOL
UA114490C2 (uk)	2011-10-06	2017-06-26	Байєр Інтеллектуал Проперті Гмбх	Гетероциклілпіри(mі)динілпіразоли як фунгіциди
KR101665231B1 (ko) *	2015-01-30	2016-10-13	순천향대학교 산학협력단	티오페닐 그룹을 갖는 티아졸계 화합물 및 이를 유효성분으로 포함하는 항진균제
CA3030582A1 (en) *	2015-07-22	2017-01-26	The Royal Institution For The Advancement Of Learning/Mcgill University	Compounds and uses thereof in the treatment of cancers and other medical conditions
US20180296478A1 (en) *	2016-02-12	2018-10-18	Synergistic Therapeutics, Llc	Sublingual antidepressant and antianxiety tablet
CN107050021B (zh) *	2017-01-23	2019-11-26	广州中大南沙科技创新产业园有限公司	噻唑酰胺衍生物在制备抗骨质疏松药物中的应用
CN109293652B (zh) *	2017-07-24	2021-10-22	四川科伦博泰生物医药股份有限公司	一种取代的噻唑衍生物及其用途
CN114105902B (zh) *	2018-12-28	2023-11-03	中山大学	噻唑苯甲酰胺衍生物及其在制备抗骨质疏松药物中的应用
CN109939109B (zh) *	2018-12-28	2021-03-23	中山大学	N-噻唑-乙酰胺衍生物作为破骨细胞分化抑制剂在制备抗骨质疏松药物中的应用
GB202011996D0 (en) *	2020-07-31	2020-09-16	Adorx Therapeutics Ltd	Antagonist compounds

Citations (5)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO2000063204A2 (en) *	1999-04-14	2000-10-26	Novartis Ag	Substituted azoles
WO2000064894A1 (fr) *	1999-04-23	2000-11-02	Takeda Chemical Industries, Ltd.	Composes 5-pyridyle-1,3-azole, leur procede de fabrication et leur utilisation
WO2000075131A1 (fr) *	1999-06-03	2000-12-14	Teikoku Hormone Mfg. Co., Ltd.	Composes a base de pyrazole substitue
WO2001001986A1 (en) *	1999-07-02	2001-01-11	Lipton Stuart A	Method of reducing neuronal injury or apoptosis
WO2001010865A1 (fr) *	1999-08-06	2001-02-15	Takeda Chemical Industries, Ltd.	INHIBITEURS DE p38MAP KINASE

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6046208A (en) *	1996-01-11	2000-04-04	Smithkline Beecham Corporation	Substituted imidazole compounds

2002
- 2002-06-10 CA CA002450400A patent/CA2450400A1/en not_active Abandoned
- 2002-06-10 EP EP20020733431 patent/EP1402900A1/en not_active Withdrawn
- 2002-06-10 US US10/480,551 patent/US20050080113A1/en not_active Abandoned
- 2002-06-10 WO PCT/JP2002/005726 patent/WO2002100433A1/ja not_active Application Discontinuation

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO2000063204A2 (en) *	1999-04-14	2000-10-26	Novartis Ag	Substituted azoles
WO2000064894A1 (fr) *	1999-04-23	2000-11-02	Takeda Chemical Industries, Ltd.	Composes 5-pyridyle-1,3-azole, leur procede de fabrication et leur utilisation
WO2000075131A1 (fr) *	1999-06-03	2000-12-14	Teikoku Hormone Mfg. Co., Ltd.	Composes a base de pyrazole substitue
WO2001001986A1 (en) *	1999-07-02	2001-01-11	Lipton Stuart A	Method of reducing neuronal injury or apoptosis
WO2001010865A1 (fr) *	1999-08-06	2001-02-15	Takeda Chemical Industries, Ltd.	INHIBITEURS DE p38MAP KINASE

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
CHU I. ET AL.: "Validation of higher-throughput high-performance liquid chromatography/atmospheric pressure chemical ionization tandem mass spectrometry assays to conduct cytochrome P450s CYP2D6 and CYP3A4 enzyme inhibition studies in human liver microsomes", RAPID COMMUN. MASS. SPECTROM., vol. 14, no. 4, 2000, pages 207 - 214, XP002955900 *
MATSUMOTO MASAHITO ET AL.: "Activation of p38 mitogen-activated protein kinase is crucial in osteoclastogenesis induced by tumor necrosis factor", FEBS LETTERS, vol. 486, no. 1, 2000, pages 23 - 28, XP002955899 *

Cited By (20)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO2004021988A3 (en) *	2002-09-05	2004-08-26	Scios Inc	Treatment of pain by inhibition of p38 map kinase
WO2004021988A2 (en) *	2002-09-05	2004-03-18	Scios Inc.	Treatment of pain by inhibition of p38 map kinase
WO2004026307A1 (en) *	2002-09-18	2004-04-01	Pfizer Products Inc.	Triazole derivatives as transforming growth factor (tgf) inhibitors
US7053095B2 (en)	2002-09-18	2006-05-30	Pfizer Inc.	Triazole compounds as transforming growth factor (TGF) inhibitors
US7273936B2 (en)	2002-09-18	2007-09-25	Pfizer Inc.	Oxazole and thiazole compounds as transforming growth factor (TGF) inhibitors
US20130267509A1 (en) *	2003-12-26	2013-10-10	Kyowa Hakko Kirin Co., Ltd.	Thiazole derivatives
US8889718B2 (en) *	2003-12-26	2014-11-18	Kyowa Hakko Kirin Co., Ltd.	Thiazole derivatives
US7410988B2 (en)	2004-08-13	2008-08-12	Genentech, Inc.	2-Amido-thiazole-based compounds exhibiting ATP-utilizing enzyme inhibitory activity, and compositions, and uses thereof
US7795290B2 (en)	2004-08-13	2010-09-14	Genentech, Inc.	2-amido-thiazole-based compounds exhibiting ATP-utilizing enzyme inhibitory activity, and compositions, and uses thereof
WO2006137658A1 (en) *	2005-06-20	2006-12-28	Dongbu Hitek Co., Ltd.	New substituted 1,3-thiazole derivatives or pharmaceutically acceptable salts thereof having immunosuppression and inflammation inhibitory acitivity, intermediate compounds or pharmaceutically acceptable salts thereof, a process for the preparation thereof, and pharmaceutical composition comprising the same
WO2006137527A1 (ja)	2005-06-23	2006-12-28	Kyowa Hakko Kogyo Co., Ltd.	チアゾール誘導体
US8063084B2 (en)	2006-08-15	2011-11-22	Novartis Ag	Heterocyclic compounds suitable for the treatment of diseases related to elevated lipid levels
US8293768B2 (en)	2006-08-15	2012-10-23	Novartis Ag	Organic compounds
US8318949B2 (en)	2008-02-20	2012-11-27	Novartis Ag	Organic compounds
US8049016B2 (en)	2008-02-20	2011-11-01	Novartis Ag	Thiazole derivatives which inhibit stearoyl-CoA desaturase enzymes
US9663529B2 (en)	2013-07-02	2017-05-30	Bristol-Myers Squibb Company	Tricyclic pyrido-carboxamide derivatives as rock inhibitors
US9914740B2 (en)	2013-07-02	2018-03-13	Bristol-Myers Squibb Company	Tricyclic pyrido-carboxamide derivatives as rock inhibitors
CN111757881A (zh) *	2018-01-15	2020-10-09	澳升控股有限公司	作为治疗剂的5-(嘧啶-4-基)噻唑-2-基脲衍生物
JP2021510704A (ja) *	2018-01-15	2021-04-30	オーセントラホールディングスピーティーワイエルティーディーＡｕｃｅｎｔｒａＨｏｌｄｉｎｇｓＰｔｙＬｔｄ	治療薬としての５−（ピリミジン−４−イル）チアゾール−２−イル尿素誘導体
JP7406808B2 (ja)	2018-01-15	2023-12-28	オーセントラセラピュティクスピーティーワイエルティーディー	治療薬としての５－（ピリミジン－４－イル）チアゾール－２－イル尿素誘導体

Also Published As

Publication number	Publication date
EP1402900A1 (en)	2004-03-31
CA2450400A1 (en)	2002-12-19
US20050080113A1 (en)	2005-04-14

Legal Events

Date	Code	Title	Description
2002-12-19	AK	Designated states	Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZM ZW
2002-12-19	AL	Designated countries for regional patents	Kind code of ref document: A1 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG
2003-01-23	DFPE	Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
2003-02-26	121	Ep: the epo has been informed by wipo that ep was designated in this application
2003-12-10	WWE	Wipo information: entry into national phase	Ref document number: 2450400 Country of ref document: CA
2003-12-11	WWE	Wipo information: entry into national phase	Ref document number: 10480551 Country of ref document: US
2003-12-12	WWE	Wipo information: entry into national phase	Ref document number: 2002733431 Country of ref document: EP
2004-03-31	WWP	Wipo information: published in national office	Ref document number: 2002733431 Country of ref document: EP
2004-04-22	REG	Reference to national code	Ref country code: DE Ref legal event code: 8642
2004-12-14	NENP	Non-entry into the national phase	Ref country code: JP
2006-08-24	WWW	Wipo information: withdrawn in national office	Ref document number: 2002733431 Country of ref document: EP

Publication	Publication Date	Title
WO2002100433A1 (en)	2002-12-19	Medicinal compositions
EP1205478A4 (en)	2004-06-30	P38MAP KINASE INHIBITORS
WO2004105757A3 (en)	2005-05-12	Use of rho-kinase inhibitors in the treatment of aneurysm and cardiac hypertrophy
MX2007002324A (es)	2007-05-11	Derivados de pirrolo[2-3-c]piridina y procesos para la preparacion de los mismos.
WO2002046171A3 (en)	2003-01-23	Anilinopyrimidine derivatives as ikk inhibitors and compositions and methods related thereto
WO2001005390A3 (en)	2001-05-17	Method for treating chronic pain using mek inhibitors
WO2005047244A3 (en)	2006-12-21	Inhibition of fgfr3 and treatment of multiple myeloma
WO2001072728A3 (en)	2002-07-18	Novel piperazine derivatives
AU2721402A (en)	2002-06-18	Anilinopyrimidine derivatives as jnk pathway inhibitors and compositions and methods related thereto
WO2003065992A3 (en)	2004-02-26	Treating benign prostate hyperplasia with sarms
WO2004018419A3 (en)	2004-06-03	Benzimidazole quinolinones and uses thereof
IL153779A0 (en)	2003-07-31	Benzoylpyridine derivative or its salt, fungicide containing it as an active ingredient, its production process and intermediate for producing it
HK1105977A1 (en)	2008-02-29	Pyrrolo [3,2-c] pyridine derivatives and processes for the preparation
WO2001085201A3 (en)	2002-05-10	Use of il-18 inhibitors for the treatment and/or prevention of atherosclerosis
WO2001056573A8 (en)	2001-11-01	Use of cox-2 inhibitors as gastroprokinetics
WO2002016312A3 (de)	2002-06-20	NEUE VERBINDUNGEN, DIE FAKTOR Xa-AKTIVITÄT INHIBIEREN
WO2004021988A3 (en)	2004-08-26	Treatment of pain by inhibition of p38 map kinase
WO2003037863A3 (de)	2004-08-12	Substituierte indole, verfahren zu deren herstellung und deren verwendung zur schmerzbekämpfung
WO2005016327A3 (en)	2005-04-14	Treatment of sleep disorders with cholinesterase inhibitors
WO2001092274A3 (en)	2002-05-30	Naaladase inhibitors for treating retinal disorders and glaucoma
WO2003035613A3 (en)	2004-01-29	Nitrogen heterocycle inhibitors of aspartyl protease
EP2016944A3 (en)	2009-12-02	Angiogenesis inhibitor containing a derivative of rifampicin
WO2003018014A3 (en)	2004-01-29	Methods of inhibiting formation of vascular channels and profileration using pyridinone derivatives
CA2183234A1 (en)	1995-08-24	Agent for prophylaxis and treatment of thromboxane a2-mediated diseases
WO2003035046A3 (en)	2003-12-24	Salts formed of an at1-receptor antagonist and a cardiovascular agent